Independent Commissioning Agent (Owner’s Advocate) Services for U.S. Army Medical Research Institute of Infectious Diseases
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
ARMY MED RES ACQ ACTIVITY
Contract Value
Not provided
Codes & Classification
Solicitation Number
EMO-26-0001
NAICS
541330 - Engineering Services
Classification Code
-
Additional Details
Documents2
The Defense Health Agency Contracting Activity (DHACA), R&D Contracting Division 1 - Branch 4, is seeking industry feedback and capability statements for Independent Commissioning Agent (Owner’s Advocate) Services at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), located at Fort Detrick, Frederick, Maryland. This request for information (RFI)/sources sought (SS) notice, under procurement identifier EMO-26-0001, is intended to inform acquisition strategy and assess marketplace capabilities for a future requirement, not to solicit offers or form binding contracts.
Purpose and Scope:
The primary objective of this procurement is to secure an independent, third-party technical Commissioning Agent to serve as the Owner’s Advocate during the transition of USAMRIID operations from its legacy facility (Building 1425) to the newly constructed Building 8100. USAMRIID is the Department of Defense’s premier laboratory for biological defense research, uniquely equipped for Biosafety Level 4 (BSL-4) containment. Building 8100, a state-of-the-art replacement facility, suffered significant infrastructure damage during a 2013 fire, complicating the transition and operational handover. The Commissioning Agent will bridge the technical gap between the U.S. Army Corps of Engineers (USACE), which manages primary repairs and construction, and the stringent operational, biosafety, and regulatory requirements of USAMRIID and its headquarters.
Key Requirements and Expected Deliverables:
The Commissioning Agent will not be responsible for architectural design, engineering drawing certification, or physical facility redesign. Instead, the role focuses on independent evaluation, witnessing, and verification of critical facility systems and controls. The agent will systematically advise the Government on executing a staggered/phased transition to achieve functional occupancy, biosafety accreditation, and facility registration. Specific areas of expertise required include:
- Experience with BSL-3 and BSL-4 containment facilities, including negative pressure cascades, Bubble Tight Dampers (BTDs), APR doors, chemical suit shower skids, and effluent decontamination systems.
- Regulatory compliance, including gap analyses, Federal Select Agent Program (FSAP) registration, Tier 1 physical security layouts, and secure tracking registers.
- Commissioning and operational systems verification, such as on-site witnessing of containment failure scenarios, safety interlock testing, and critical review of commissioning reports.
- Project management as an independent Owner’s Advocate, facilitating phased transitions without organizational conflicts of interest.
Respondents must demonstrate organizational independence from the facility’s prime construction contractors and certify compliance with FAR RFO 9.5 regarding conflicts of interest.
Facility Parameters:
Building 8100 encompasses approximately 835,000 gross square feet, including:
- 310,000 GSF of administrative and headquarters spaces
- 185,000 GSF of BSL-1 and BSL-2 laboratory spaces
- 65,208 GSF of ABSL-2 vivarium
- 165,000 GSF of BSL-3, ABSL-3, and ACL-3 containment suites
- 65,000 GSF of BSL-4 and ABSL-4 maximum containment (including suit suites, chemical suit shower corridors, and airlocks)
- 110,000 GSF of central utility and mechanical support
- 12 double-door pass-through containment autoclaves
- Continuous-flow thermal effluent decontamination system (EDS) with a 150 gpm design flow
The anticipated period of performance is a non-severable 60-month term, with regular on-site presence required during active functional and failure-testing windows.
Contracting Entity and Classification:
The contracting entity is the Army Medical Research Acquisition Activity, a federal office under the Department of Defense and the Defense Health Agency. The procurement is classified under NAICS code 541330 (Engineering Services), version year 2022. The place of performance is Frederick, Maryland.
Procurement Type and Set-Aside Considerations:
This notice is a sources sought/RFI, not a solicitation. The Government will use responses to determine whether the acquisition can be set aside for small business concerns (including 8(a), SDVOSB, WOSB, or HUBZone programs) or if full and open competition is required. The contemplated contract type is Firm-Fixed-Price with Performance-Based Milestone Payments (FAR RFO 32.10), with payouts tied to measurable events and transition milestones.
Special Considerations:
Respondents are requested to submit capability statements (maximum 15 pages) detailing relevant experience, company information, government contract vehicles, and organizational independence. Technical responses should address biocontainment qualifications, regulatory compliance, commissioning experience, and project management. Industry feedback is sought on phased occupancy strategies, compliance tracking, deliverable timelines, government-furnished property needs, industry day preferences, oral presentation evaluation methods, and contract type feasibility. A non-binding Rough Order of Magnitude pricing estimate is also requested, with narrative explanations of cost drivers and labor categories.
Contact Information:
Primary Contact: Elizabeth O'Hara, Contract Specialist ([email protected])
Secondary Contact: Amanda Best ([email protected])
Submission Details:
Responses are due no later than November 9, 2026, at 12:00 PM ET, submitted electronically in PDF or MS Word format to the primary contact. All responses will be considered, but the Government reserves discretion regarding solicitation and may continue market research as needed.
For further information and attachments, refer to the official notice at https://sam.gov/opp/b94f951434e24a1fa3b0570e378b1ae5/view.
This opportunity is well-suited for firms with demonstrated expertise in commissioning high-containment biological research facilities, regulatory compliance, and independent project management. Contractors should assess their capabilities against the outlined requirements and consider the long-term, complex nature of the engagement at USAMRIID’s Building 8100.